Viatris Reports Strong Fourth Quarter and Full Year 2022 Fin

/PRNewswire/ -- Company Meets its 2022 Adjusted Guidance After Incorporating the Fourth Quarter Impact of the Biosimilars Transaction and Acquired IPR&D 2023...

Related Keywords

China , Shanghai , United States , India , Hyderabad , Andhra Pradesh , America , Rajiv Malik , Sanjeev Narula , Michael Goettler , Biocon Biologics , Company Annual Report On Form , Youtube , Linkedin , Viatris Inc , Nasdaq , Company Increases Return Of Capital To Shareholders , Guidance After Incorporating , Fourth Quarter Impact , Biosimilars Transaction , Midpoint Reflects Revenue Growth Over , Excluding Full Year Impact , Increases Return , Directors Approves , Forty Eight Cents , Declares First Quarter Dividend , Twelve Cents , Down Debt , Debt Since , Execute Planned , Key Terms , Viatri Board , President Rajiv Malik , Full Year , Period Presentation , North America , Total Revenues , Financial Condition , Viatri Annual Report , Global Healthcare Gateway , Private Securities Litigation Reform Act , Annual Report , Fair Disclosure , Viatri Phase , Consolidated Statements , Product Net Sales , Key Global Products , Key Segment Products , Adjusted Net , Ended December , Upjohn Distributor Markets , Developed Markets , Emerging Markets , Operations Line , Revenue Code , Cash Provided , Operating Activities , Free Cash , Free Cash Flow ,